Journal article 236 views 190 downloads
Brain cholesterol and Alzheimer’s disease: challenges and opportunities in probe and drug development
Brain
Swansea University Authors:
Yuqin Wang , William Griffiths
-
PDF | Accepted Manuscript
For the purpose of Open Access, the authors have applied a CC BY public copyright license to any Author Accepted Manuscript version arising from this submission.
Download (848.15KB)
DOI (Published version): 10.1093/brain/awae028
Abstract
Cholesterol homeostasis is impaired in Alzheimer’s disease (AD), however, attempts to modulate brain cholesterol biology have not translated into tangible clinical benefits for patients to date. Several recent milestone developments have substantially improved our understanding of how excess neurona...
Published in: | Brain |
---|---|
ISSN: | 0006-8950 1460-2156 |
Published: |
Oxford University Press (OUP)
2024
|
Online Access: |
Check full text
|
URI: | https://cronfa.swan.ac.uk/Record/cronfa65566 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
first_indexed |
2024-02-04T14:54:39Z |
---|---|
last_indexed |
2024-02-04T14:54:39Z |
id |
cronfa65566 |
recordtype |
SURis |
fullrecord |
<?xml version="1.0" encoding="utf-8"?><rfc1807 xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema"><bib-version>v2</bib-version><id>65566</id><entry>2024-02-04</entry><title>Brain cholesterol and Alzheimer’s disease: challenges and opportunities in probe and drug development</title><swanseaauthors><author><sid>c92729b58622f9fdf6a0e7d8f4ce5081</sid><ORCID>0000-0002-3063-3066</ORCID><firstname>Yuqin</firstname><surname>Wang</surname><name>Yuqin Wang</name><active>true</active><ethesisStudent>false</ethesisStudent></author><author><sid>3316b1d1b524be1831790933eed1c26e</sid><ORCID>0000-0002-4129-6616</ORCID><firstname>William</firstname><surname>Griffiths</surname><name>William Griffiths</name><active>true</active><ethesisStudent>false</ethesisStudent></author></swanseaauthors><date>2024-02-04</date><deptcode>BMS</deptcode><abstract>Cholesterol homeostasis is impaired in Alzheimer’s disease (AD), however, attempts to modulate brain cholesterol biology have not translated into tangible clinical benefits for patients to date. Several recent milestone developments have substantially improved our understanding of how excess neuronal cholesterol contributes to the pathophysiology of AD. Indeed, neuronal cholesterol was linked to the formation of amyloid-β (Aβ) and neurofibrillary tangles through molecular pathways that were recently delineated in mechanistic studies. Further, remarkable advances in translational molecular imaging have now made it possible to probe cholesterol metabolism in the living human brain with positron emission tomography, which is an important prerequisite for future clinical trials that target the brain cholesterol machinery in AD patients – with the ultimate aim to develop disease-modifying treatments. This work summarizes current concepts of how the biosynthesis, transport and clearance of brain cholesterol are affected in AD. Further, current strategies to reverse these alterations by pharmacotherapy are critically discussed in the wake of emerging translational research tools that support the assessment of brain cholesterol biology not only in animal models but also in AD patients.</abstract><type>Journal Article</type><journal>Brain</journal><volume>0</volume><journalNumber/><paginationStart/><paginationEnd/><publisher>Oxford University Press (OUP)</publisher><placeOfPublication/><isbnPrint/><isbnElectronic/><issnPrint>0006-8950</issnPrint><issnElectronic>1460-2156</issnElectronic><keywords>brain cholesterol homeostasis, Alzheimer’s disease, cholesterol lowering therapy, translational molecular imaging, cytochrome P450 46A1 (CYP46A1)</keywords><publishedDay>1</publishedDay><publishedMonth>2</publishedMonth><publishedYear>2024</publishedYear><publishedDate>2024-02-01</publishedDate><doi>10.1093/brain/awae028</doi><url/><notes/><college>COLLEGE NANME</college><department>Biomedical Sciences</department><CollegeCode>COLLEGE CODE</CollegeCode><DepartmentCode>BMS</DepartmentCode><institution>Swansea University</institution><apcterm>Not Required</apcterm><funders/><projectreference/><lastEdited>2024-04-07T13:01:19.1960416</lastEdited><Created>2024-02-04T14:43:03.4590648</Created><path><level id="1">Faculty of Medicine, Health and Life Sciences</level><level id="2">Swansea University Medical School - Biomedical Science</level></path><authors><author><firstname>Hazem</firstname><surname>Ahmed</surname><orcid>0000-0001-7047-5202</orcid><order>1</order></author><author><firstname>Yuqin</firstname><surname>Wang</surname><orcid>0000-0002-3063-3066</orcid><order>2</order></author><author><firstname>William</firstname><surname>Griffiths</surname><orcid>0000-0002-4129-6616</orcid><order>3</order></author><author><firstname>Allan I</firstname><surname>Levey</surname><order>4</order></author><author><firstname>Irina</firstname><surname>Pikuleva</surname><orcid>0000-0001-9742-6232</orcid><order>5</order></author><author><firstname>Steven H</firstname><surname>Liang</surname><order>6</order></author><author><firstname>Ahmed</firstname><surname>Haider</surname><orcid>0000-0002-5204-4473</orcid><order>7</order></author></authors><documents><document><filename>65566__29511__df02c4a1a6b844d8a511cc5437720fc9.pdf</filename><originalFilename>awae028.pdf</originalFilename><uploaded>2024-02-04T14:54:09.2611976</uploaded><type>Output</type><contentLength>868509</contentLength><contentType>application/pdf</contentType><version>Accepted Manuscript</version><cronfaStatus>true</cronfaStatus><documentNotes>For the purpose of Open Access, the authors have applied a CC BY public copyright license to any Author Accepted Manuscript version arising from this submission.</documentNotes><copyrightCorrect>true</copyrightCorrect><language>eng</language><licence>https://creativecommons.org/licenses/by/4.0/</licence></document></documents><OutputDurs/></rfc1807> |
spelling |
v2 65566 2024-02-04 Brain cholesterol and Alzheimer’s disease: challenges and opportunities in probe and drug development c92729b58622f9fdf6a0e7d8f4ce5081 0000-0002-3063-3066 Yuqin Wang Yuqin Wang true false 3316b1d1b524be1831790933eed1c26e 0000-0002-4129-6616 William Griffiths William Griffiths true false 2024-02-04 BMS Cholesterol homeostasis is impaired in Alzheimer’s disease (AD), however, attempts to modulate brain cholesterol biology have not translated into tangible clinical benefits for patients to date. Several recent milestone developments have substantially improved our understanding of how excess neuronal cholesterol contributes to the pathophysiology of AD. Indeed, neuronal cholesterol was linked to the formation of amyloid-β (Aβ) and neurofibrillary tangles through molecular pathways that were recently delineated in mechanistic studies. Further, remarkable advances in translational molecular imaging have now made it possible to probe cholesterol metabolism in the living human brain with positron emission tomography, which is an important prerequisite for future clinical trials that target the brain cholesterol machinery in AD patients – with the ultimate aim to develop disease-modifying treatments. This work summarizes current concepts of how the biosynthesis, transport and clearance of brain cholesterol are affected in AD. Further, current strategies to reverse these alterations by pharmacotherapy are critically discussed in the wake of emerging translational research tools that support the assessment of brain cholesterol biology not only in animal models but also in AD patients. Journal Article Brain 0 Oxford University Press (OUP) 0006-8950 1460-2156 brain cholesterol homeostasis, Alzheimer’s disease, cholesterol lowering therapy, translational molecular imaging, cytochrome P450 46A1 (CYP46A1) 1 2 2024 2024-02-01 10.1093/brain/awae028 COLLEGE NANME Biomedical Sciences COLLEGE CODE BMS Swansea University Not Required 2024-04-07T13:01:19.1960416 2024-02-04T14:43:03.4590648 Faculty of Medicine, Health and Life Sciences Swansea University Medical School - Biomedical Science Hazem Ahmed 0000-0001-7047-5202 1 Yuqin Wang 0000-0002-3063-3066 2 William Griffiths 0000-0002-4129-6616 3 Allan I Levey 4 Irina Pikuleva 0000-0001-9742-6232 5 Steven H Liang 6 Ahmed Haider 0000-0002-5204-4473 7 65566__29511__df02c4a1a6b844d8a511cc5437720fc9.pdf awae028.pdf 2024-02-04T14:54:09.2611976 Output 868509 application/pdf Accepted Manuscript true For the purpose of Open Access, the authors have applied a CC BY public copyright license to any Author Accepted Manuscript version arising from this submission. true eng https://creativecommons.org/licenses/by/4.0/ |
title |
Brain cholesterol and Alzheimer’s disease: challenges and opportunities in probe and drug development |
spellingShingle |
Brain cholesterol and Alzheimer’s disease: challenges and opportunities in probe and drug development Yuqin Wang William Griffiths |
title_short |
Brain cholesterol and Alzheimer’s disease: challenges and opportunities in probe and drug development |
title_full |
Brain cholesterol and Alzheimer’s disease: challenges and opportunities in probe and drug development |
title_fullStr |
Brain cholesterol and Alzheimer’s disease: challenges and opportunities in probe and drug development |
title_full_unstemmed |
Brain cholesterol and Alzheimer’s disease: challenges and opportunities in probe and drug development |
title_sort |
Brain cholesterol and Alzheimer’s disease: challenges and opportunities in probe and drug development |
author_id_str_mv |
c92729b58622f9fdf6a0e7d8f4ce5081 3316b1d1b524be1831790933eed1c26e |
author_id_fullname_str_mv |
c92729b58622f9fdf6a0e7d8f4ce5081_***_Yuqin Wang 3316b1d1b524be1831790933eed1c26e_***_William Griffiths |
author |
Yuqin Wang William Griffiths |
author2 |
Hazem Ahmed Yuqin Wang William Griffiths Allan I Levey Irina Pikuleva Steven H Liang Ahmed Haider |
format |
Journal article |
container_title |
Brain |
container_volume |
0 |
publishDate |
2024 |
institution |
Swansea University |
issn |
0006-8950 1460-2156 |
doi_str_mv |
10.1093/brain/awae028 |
publisher |
Oxford University Press (OUP) |
college_str |
Faculty of Medicine, Health and Life Sciences |
hierarchytype |
|
hierarchy_top_id |
facultyofmedicinehealthandlifesciences |
hierarchy_top_title |
Faculty of Medicine, Health and Life Sciences |
hierarchy_parent_id |
facultyofmedicinehealthandlifesciences |
hierarchy_parent_title |
Faculty of Medicine, Health and Life Sciences |
department_str |
Swansea University Medical School - Biomedical Science{{{_:::_}}}Faculty of Medicine, Health and Life Sciences{{{_:::_}}}Swansea University Medical School - Biomedical Science |
document_store_str |
1 |
active_str |
0 |
description |
Cholesterol homeostasis is impaired in Alzheimer’s disease (AD), however, attempts to modulate brain cholesterol biology have not translated into tangible clinical benefits for patients to date. Several recent milestone developments have substantially improved our understanding of how excess neuronal cholesterol contributes to the pathophysiology of AD. Indeed, neuronal cholesterol was linked to the formation of amyloid-β (Aβ) and neurofibrillary tangles through molecular pathways that were recently delineated in mechanistic studies. Further, remarkable advances in translational molecular imaging have now made it possible to probe cholesterol metabolism in the living human brain with positron emission tomography, which is an important prerequisite for future clinical trials that target the brain cholesterol machinery in AD patients – with the ultimate aim to develop disease-modifying treatments. This work summarizes current concepts of how the biosynthesis, transport and clearance of brain cholesterol are affected in AD. Further, current strategies to reverse these alterations by pharmacotherapy are critically discussed in the wake of emerging translational research tools that support the assessment of brain cholesterol biology not only in animal models but also in AD patients. |
published_date |
2024-02-01T13:01:16Z |
_version_ |
1795677252373970944 |
score |
11.021648 |